L-DOPA, a treatment for Parkinson's disease, and its enantiomer D-DOPA inhibit severe fever with thrombocytopenia syndrome virus infection in vitro
| Autor: | Masayuki Saijo, Masayoshi Fukasawa, Kohji Noguchi, Takuya Irie, Masayuki Shimojima, Motohiko Ogawa, Mana Murae, Ryutaro Gemba |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Microbiology (medical)
Phlebovirus Parkinson's disease Hemorrhagic Fevers Viral Side effect Severe Fever with Thrombocytopenia Syndrome Bunyaviridae Infections Levodopa Oral administration medicine Humans Pharmacology (medical) IC50 Leukopenia biology business.industry SFTS virus Parkinson Disease medicine.disease biology.organism_classification Thrombocytopenia nervous system diseases Severe fever with thrombocytopenia syndrome Infectious Diseases Immunology medicine.symptom business Severe fever with thrombocytopenia syndrome virus |
| Zdroj: | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 28(3) |
| ISSN: | 1437-7780 |
| Popis: | Severe fever with thrombocytopenia syndrome (SFTS) is a hemorrhagic fever. Patients mainly develop fever, thrombocytopenia, and leukopenia. A high case fatality rate of 16.2–47% has been reported. Vaccines and antivirals that are effective against SFTS virus (SFTSV) are not yet available in clinical practice. We previously showed that o-dihydroxybenzene is the important chemical core structure for anti-SFTSV activity. In this study, we evaluated the anti-SFTSV efficacy of 3-Hydroxy-L-tyrosine (L-DOPA), a treatment for Parkinson's disease and its enantiomer, 3-hydroxy-D-tyrosine (D-DOPA), both of which have an o-dihydroxybenzene backbone. SFTSV was preincubated with L- or D-DOPA and then inhibition of viral infection as well as viral attachment to host cells were evaluated by viral quantification. Both L- and D-DOPA inhibited SFTSV infection in a dose-dependent manner, mainly by blocking viral attachment to host cells. The half-maximal inhibitory concentration (IC50) of L-DOPA was 4.46–5.09 μM. IC50 of D-DOPA was 4.23–6.72 μM. IC50 of L-DOPA is very close to its maximum blood concentration after oral administration as a therapy for Parkinson's disease. D-DOPA, which IC50 was almost the same as that of L-DOPA, might not cause side effect. Thus, our present study demonstrated that L- and D-DOPA are potentially useful candidates for anti-SFTSV drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect